The full text of this article


International differences in cancer survival rates: the role of new drug launches
by Frank R. Lichtenberg
International Journal of Healthcare Technology and Management (IJHTM), Vol. 10, No. 3, 2009


Abstract: We investigate the effect of availability of new drugs on survival from 17 types of cancer in 38 countries, controlling for all determinants of cancer survival that are invariant across cancer types within a given country, and that are invariant across countries for a given cancer type. We find that an increase in the number of available drugs is associated with an increase in both the one-year and the five-year survival rate. Also, the probability that a cancer drug has been launched in a country depends on the incidence of cancer cases eligible for treatment by that drug in that country.

Online publication date: Sun, 24-May-2009


is only available to individual subscribers or to users at subscribing institutions.

Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Healthcare Technology and Management (IJHTM):
Login with your Inderscience username and password:


    Username:        Password:         

Forgotten your password?

Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email